Compugen Ltd CGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGEN is a good fit for your portfolio.
News
-
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
-
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
-
Compugen to Participate in Two Upcoming Investor Conferences
-
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
-
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
-
Compugen Reports Fourth Quarter and Full Year 2023 Results
-
Thinking about buying stock in Volcon, Abeona Therapeutics, Agenus, Viking Therapeutics, or Compugen?
-
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
Trading Information
- Previous Close Price
- $1.98
- Day Range
- $1.88–1.98
- 52-Week Range
- $0.53–3.03
- Bid/Ask
- $1.91 / $1.99
- Market Cap
- $172.79 Mil
- Volume/Avg
- 274,515 / 505,929
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 68
- Website
- https://www.cgen.com
Comparables
Valuation
|
Metric
|
CGEN
|
RCUS
|
GMDAQ
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.70 | 2.55 | — |
Price/Sales | 5.19 | 9.89 | 1.00 |
Price/Cash Flow | — | — | — |
Price/Earnings
CGEN
RCUS
GMDAQ
Financial Strength
|
Metric
|
CGEN
|
RCUS
|
GMDAQ
|
|---|---|---|---|
Quick Ratio | 4.26 | 4.35 | 1.91 |
Current Ratio | 4.36 | 4.52 | 2.16 |
Interest Coverage | — | −170.00 | −7.66 |
Quick Ratio
CGEN
RCUS
GMDAQ
Profitability
|
Metric
|
CGEN
|
RCUS
|
GMDAQ
|
|---|---|---|---|
Return on Assets (Normalized) | −18.13% | −20.42% | −65.75% |
Return on Equity (Normalized) | −24.59% | −44.44% | — |
Return on Invested Capital (Normalized) | −27.39% | −49.53% | −84.89% |
Return on Assets
CGEN
RCUS
GMDAQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xnjzpqwyx | Dzvb | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qpshcmy | Qysljpy | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qcsntvhhc | Xgglkxd | $98.3 Bil | |
MRNA
| Moderna Inc | Lktzqsqg | Sglrk | $42.7 Bil | |
ARGX
| argenx SE ADR | Dmhphgbh | Fflf | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Zstzxsqhb | Cqrvc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hbvtsjv | Ctwzvy | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fcbsfgld | Fnsfhl | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gcvzbzbgs | Zsyksr | $12.7 Bil | |
INCY
| Incyte Corp | Blrdzwcys | Dnkfrb | $11.8 Bil |